{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:52:30Z","timestamp":1782532350683,"version":"3.54.5"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":1255,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Tyrosine kinase inhibitor (TKI)\u2013treated chronic myeloid leukemia (CML) patients with increased NK cell number have a better prognosis, and thus, NK cells may suppress CML. However, the efficacy of TKIs varies for reasons yet to be fully elucidated. As NK cell activity is modulated by interactions between their killer cell Ig-like receptors (KIRs) and HLAs of target cells, the combination of their polymorphisms may have functional significance. We previously showed that allelic polymorphisms of KIR3DL1 and HLAs were associated with the prognosis of TKI-treated CML patients. In this study, we focus on differential NK cell activity modulation through KIR3DL1 allotypes. KIR3DL1 expression levels varied according to their alleles. The combination of KIR3DL1 expression level and HLA-Bw4 motifs defined NK cell activity in response to the CML-derived K562 cell line, and Ab-mediated KIR3DL1 blocking reversed this activity. The TKI dasatinib enhanced NK cell activation and cytotoxicity in a KIR3DL1 allotype-dependent manner but did not significantly decrease effector regulatory T cells, suggesting that it directly activated NK cells. Dasatinib also enhanced NK cell cytotoxicity against K562 bearing the BCR-ABL1 T315I TKI resistance\u2013conferring mutation, depending on KIR3DL1\/HLA-Bw4 allotypes. Transduction of KIR3DL1*01502 into the NK cell line NK-92 resulted in KIR3DL1 expression and suppression of NK-92 activity by HLA-B ligation, which was reversed by anti-KIR3DL1 Ab. Finally, KIR3DL1 expression levels also defined activation patterns in CML patient\u2013derived NK cells. Our findings raise the possibility of a novel strategy to enhance antitumor NK cell immunity against CML in a KIR3DL1 allotype-dependent manner.<\/jats:p>","DOI":"10.4049\/immunohorizons.2100054","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T15:55:12Z","timestamp":1629906912000},"page":"687-702","source":"Crossref","is-referenced-by-count":5,"title":["KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia"],"prefix":"10.1093","volume":"5","author":[{"given":"Kiyotaka","family":"Izumi","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Kyoto University Graduate School of Medicine , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2085-6151","authenticated-orcid":false,"given":"Takero","family":"Shindo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Kyoto University Graduate School of Medicine , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huong Thi","family":"Ngo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Kyoto University Graduate School of Medicine , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Nakayama-Hosoya","sequence":"additional","affiliation":[{"name":"AIDS Research Center, National Institute of Infectious Diseases , Tokyo , ; and","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Akahane","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Yamanashi , Chuo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minori","family":"Tamai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Yamanashi , Chuo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-167X","authenticated-orcid":false,"given":"Thao T T","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Yamanashi , Chuo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3082-5324","authenticated-orcid":false,"given":"Ai","family":"Kawana-Tachikawa","sequence":"additional","affiliation":[{"name":"AIDS Research Center, National Institute of Infectious Diseases , Tokyo , ; and","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Inukai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Yamanashi , Chuo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-4284","authenticated-orcid":false,"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Kyoto University Graduate School of Medicine , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,1]]},"reference":[{"key":"2025010703490558400_r1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2025010703490558400_r2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2025010703490558400_r3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"2025010703490558400_r4","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","article-title":"The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors","volume":"2016","author":"Efficace","year":"2016","journal-title":"Hematology (Am. Soc. Hematol. Educ. Program)."},{"key":"2025010703490558400_r5","doi-asserted-by":"crossref","first-page":"djw003","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"2025010703490558400_r6","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/bloodadvances.2019000745","article-title":"Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation","volume":"3","author":"Yamamoto","year":"2019","journal-title":"Blood Adv."},{"key":"2025010703490558400_r7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"2025010703490558400_r8","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"key":"2025010703490558400_r9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2016","journal-title":"Leukemia."},{"key":"2025010703490558400_r10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","article-title":"Human NK cell education by inhibitory receptors for MHC class I","volume":"25","author":"Anfossi","year":"2006","journal-title":"Immunity."},{"key":"2025010703490558400_r11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol. Today."},{"key":"2025010703490558400_r12","doi-asserted-by":"crossref","first-page":"eaag1672","DOI":"10.1126\/sciimmunol.aag1672","article-title":"Class I HLA haplotypes form two schools that educate NK cells in different ways","volume":"1","author":"Horowitz","year":"2016","journal-title":"Sci. Immunol."},{"key":"2025010703490558400_r13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00251-003-0572-y","article-title":"Human KIR sequences 2003","volume":"55","author":"Garcia","year":"2003","journal-title":"Immunogenetics."},{"key":"2025010703490558400_r14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2567.2009.03208.x","article-title":"The extensive polymorphism of KIR genes","volume":"129","author":"Middleton","year":"2010","journal-title":"Immunology."},{"key":"2025010703490558400_r15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1084\/jem.180.2.537","article-title":"NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules","volume":"180","author":"Litwin","year":"1994","journal-title":"J. Exp. Med."},{"key":"2025010703490558400_r16","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.4049\/jimmunol.137.11.3671","article-title":"The primary structure of HLA-A32 suggests a region involved in formation of the Bw4\/Bw6 epitopes","volume":"137","author":"Wan","year":"1986","journal-title":"J. Immunol."},{"key":"2025010703490558400_r17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/BF02421207","article-title":"Genetic and serological heterogeneity of the supertypic HLA-B locus specificities Bw4 and Bw6","volume":"30","author":"M\u00fcller","year":"1989","journal-title":"Immunogenetics."},{"key":"2025010703490558400_r18","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1084\/jem.181.3.1133","article-title":"The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor","volume":"181","author":"Gumperz","year":"1995","journal-title":"J. Exp. Med."},{"key":"2025010703490558400_r19","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.4049\/jimmunol.166.5.2992","article-title":"Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism","volume":"166","author":"Gardiner","year":"2001","journal-title":"J. Immunol."},{"key":"2025010703490558400_r20","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.4049\/jimmunol.171.12.6640","article-title":"The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1","volume":"171","author":"Pando","year":"2003","journal-title":"J. Immunol."},{"key":"2025010703490558400_r21","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/eji.200636773","article-title":"Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies","volume":"37","author":"Trundley","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"2025010703490558400_r22","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.4049\/jimmunol.180.10.6743","article-title":"Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation?","volume":"180","author":"Thomas","year":"2008","journal-title":"J. Immunol."},{"key":"2025010703490558400_r23","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.4049\/jimmunol.0901734","article-title":"Dimorphic motifs in D0 and D1+D2 domains of killer cell Ig-like receptor 3DL1 combine to form receptors with high, moderate, and no avidity for the complex of a peptide derived from HIV and HLA-A*2402","volume":"183","author":"Sharma","year":"2009","journal-title":"J. Immunol."},{"key":"2025010703490558400_r24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.0902332","article-title":"Variable NK cell receptors exemplified by human KIR3DL1\/S1","volume":"187","author":"Parham","year":"2011","journal-title":"J. Immunol."},{"key":"2025010703490558400_r25","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.4049\/jimmunol.175.8.5222","article-title":"KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand","volume":"175","author":"Carr","year":"2005","journal-title":"J. Immunol."},{"key":"2025010703490558400_r26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20051884","article-title":"Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function","volume":"203","author":"Yawata","year":"2006","journal-title":"J. Exp. Med."},{"key":"2025010703490558400_r27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4049\/jimmunol.178.1.235","article-title":"Functional polymorphism of the KIR3DL1\/S1 receptor on human NK cells","volume":"178","author":"O\u2019Connor","year":"2007","journal-title":"J. Immunol."},{"key":"2025010703490558400_r28","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.4049\/jimmunol.1502469","article-title":"KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV","volume":"196","author":"Boudreau","year":"2016","journal-title":"J. Immunol."},{"key":"2025010703490558400_r29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ng2035","article-title":"Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1","volume":"39","author":"Martin","year":"2007","journal-title":"Nat. Genet."},{"key":"2025010703490558400_r30","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1200\/JCO.2015.64.9558","article-title":"KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to Anti-GD2 monoclonal antibody in patients with neuroblastoma","volume":"34","author":"Forlenza","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2025010703490558400_r31","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1200\/JCO.2016.70.7059","article-title":"KIR3DL1\/HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation","volume":"35","author":"Boudreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"2025010703490558400_r32","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood.2019002887","article-title":"External validation of models for KIR2DS1\/KIR3DL1-informed selection of hematopoietic cell donors fails","volume":"135","author":"Schetelig","year":"2020","journal-title":"Blood."},{"key":"2025010703490558400_r33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.coi.2017.11.003","article-title":"Natural killer cell education in human health and disease","volume":"50","author":"Boudreau","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"2025010703490558400_r34","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/2326-6066.CIR-17-0462","article-title":"Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML","volume":"6","author":"Ureshino","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"2025010703490558400_r35","doi-asserted-by":"crossref","first-page":"e20191009","DOI":"10.1084\/jem.20191009","article-title":"Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells","volume":"217","author":"Tanaka","year":"2020","journal-title":"J. Exp. Med."},{"key":"2025010703490558400_r36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1158\/2326-6066.CIR-16-0061-T","article-title":"Dasatinib changes immune cell profiles concomitant with reduced tumor growth in several murine solid tumor models","volume":"5","author":"Hekim","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"2025010703490558400_r37","doi-asserted-by":"crossref","first-page":"9966","DOI":"10.1038\/s41598-018-27767-6","article-title":"T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR\/Cas9 system","volume":"8","author":"Tamai","year":"2018","journal-title":"Sci. Rep."},{"key":"2025010703490558400_r38","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1089\/hum.2012.080","article-title":"Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy","volume":"23","author":"Sutlu","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"2025010703490558400_r39","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1084\/jem.20152023","article-title":"Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition","volume":"213","author":"Saunders","year":"2016","journal-title":"J. Exp. Med."},{"key":"2025010703490558400_r40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood-2008-01-132902","article-title":"The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations","volume":"112","author":"Foley","year":"2008","journal-title":"Blood."},{"key":"2025010703490558400_r41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12865-018-0272-x","article-title":"Expression of ligands for activating natural killer cell receptors on cell lines commonly used to assess natural killer cell function","volume":"20","author":"Tremblay-McLean","year":"2019","journal-title":"BMC Immunol."},{"key":"2025010703490558400_r42","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.3389\/fimmu.2018.03152","article-title":"NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia","volume":"9","author":"Chang","year":"2019","journal-title":"Front. Immunol."},{"key":"2025010703490558400_r43","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2013-08-519199","article-title":"Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood."},{"key":"2025010703490558400_r44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41375-020-0939-1","article-title":"A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed\/refractory lymphoid malignancies","volume":"35","author":"Armand","year":"2020","journal-title":"Leukemia."},{"key":"2025010703490558400_r45","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.4049\/jimmunol.180.9.6392","article-title":"Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy","volume":"180","author":"Binyamin","year":"2008","journal-title":"J. Immunol."}],"container-title":["ImmunoHorizons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/5\/8\/687\/60188527\/ih2100054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/5\/8\/687\/60188527\/ih2100054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T03:52:41Z","timestamp":1736221961000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article\/5\/8\/687\/7820223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.4049\/immunohorizons.2100054","relation":{},"ISSN":["2573-7732"],"issn-type":[{"value":"2573-7732","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8]]},"published":{"date-parts":[[2021,8,1]]}}}